Market closed
Supernus Pharmaceuticals/$SUPN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Supernus Pharmaceuticals
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Ticker
$SUPN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
674
Website
SUPN Metrics
BasicAdvanced
$1.8B
24.88
$1.32
0.90
-
Price and volume
Market cap
$1.8B
Beta
0.9
52-week high
$40.28
52-week low
$25.53
Average daily volume
615K
Financial strength
Current ratio
2.346
Quick ratio
2.037
Long term debt to equity
2.644
Total debt to equity
3.309
Management effectiveness
Return on assets (TTM)
2.90%
Return on equity (TTM)
7.55%
Valuation
Price to earnings (TTM)
24.879
Price to revenue (TTM)
2.734
Price to book
1.77
Price to tangible book (TTM)
4.61
Price to free cash flow (TTM)
10.568
Growth
Revenue change (TTM)
8.94%
Earnings per share change (TTM)
6,500.00%
3-year revenue growth (CAGR)
4.51%
3-year earnings per share growth (CAGR)
10.44%
What the Analysts think about SUPN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Supernus Pharmaceuticals stock.
SUPN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SUPN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SUPN News
AllArticlesVideos
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN
Accesswire·6 days ago
Supernus to Participate in Two Upcoming Investor Conferences
GlobeNewsWire·1 week ago
Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Accesswire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Supernus Pharmaceuticals stock?
Supernus Pharmaceuticals (SUPN) has a market cap of $1.8B as of March 12, 2025.
What is the P/E ratio for Supernus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Supernus Pharmaceuticals (SUPN) stock is 24.88 as of March 12, 2025.
Does Supernus Pharmaceuticals stock pay dividends?
No, Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders as of March 12, 2025.
When is the next Supernus Pharmaceuticals dividend payment date?
Supernus Pharmaceuticals (SUPN) stock does not pay dividends to its shareholders.
What is the beta indicator for Supernus Pharmaceuticals?
Supernus Pharmaceuticals (SUPN) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.